

**THE SYNTHESIS OF GROUP 10 METALS
SCHIFF BASE COMPLEXES WITH ONN AND
ONS GROUPS: CHARACTERIZATION AND
THEIR CYTOTOXICITY AND ANTIBACTERIAL
ACTIVITIES**

MD AZHARUL ARAFATH

**UNIVERSITI SAINS MALAYSIA
2018**

**THE SYNTHESIS OF GROUP 10 METALS
SCHIFF BASE COMPLEXES WITH ONN AND
ONS GROUPS: CHARACTERIZATION AND
THEIR CYTOTOXICITY AND ANTIBACTERIAL
ACTIVITIES**

by

MD AZHARUL ARAFATH

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

February 2018

DEDICATION

To

*My teacher and mentor,
oasis of the honesty and principle,
the source of heavenly love and affection*

My Dear Father

LATE REAZ UDDIN

ACKNOWLEDGEMENT

All praise to the Almighty Allah for blessing me with sound health, mental strength and courage to conduct the research and write up of the PhD dissertation successfully. I would like to express my deepest acknowledgement to Universiti Sains Malaysia (USM) for giving me the opportunity to conduct the entire research smoothly with worthy facilities. I would like to acknowledge the authority of Shahjalal University of Science and Technology for granting study leave throughout my research period.

I am delighted here to extend sincere gratitude to my honourable supervisor Professor Dr. Farook Adam for his scholastic and informative guidance in research and write up of the thesis. I express profound gratitude to my dignified co-supervisors Dr. Mohd Rizal Razli for his worthy advice during my research work.

I express heartiest gratitude to The World Academy of Science (TWAS) and Universiti Sains Malaysia for (USM - TWAS) post graduate fellowship for satisfactory financial support to continue my PhD. I also admit gratitude for RU grant 1001/PKIMIA/811269 from Universiti Sains Malaysia that financially supported this research.

Sincere appreciation is forwarded to Mr. Kwong Huey Chong for X-ray diffraction data and Mr. Muhd Nizam bin Muhamad Isa for NMR data. I want to thank, Dr. Rabiatul Basria, Professor Dr. Amirul Islam, Dr. Khadeer and Dr. Fouad for biological application. I confess thankfulness to all staffs of USM for friendly cooperation and support.

I want to wish to all my family members as well friends and colleagues of USM and SUST for cordial affection and inspiring suggestion.

TABLES OF CONTENTS

Acknowledgement.....	ii
List of Tables.....	xi
List of Figures	xiii
List of Schemes	xix
List of Abbreviations and Symbols.....	xxii
Abstrak	xxvi
Abstract	xxviii
CHAPTER ONE - INTRODUCTION	1
1.1 Schiff Base Compounds.....	1
1.2 <i>N</i> -heterocyclic Schiff base compounds.....	1
1.3 Type of carbazone Schiff base compounds	2
1.3.1 Mono-thiosemicarbazone	3
1.3.2 Bis-thiosemicarbazones	3
1.4 Different molecular forms of thiosemicarbazones Schiff base compounds.	4
1.4.1 Bonding approach in neutral form.....	5
1.4.2 Bonding approach in anionic form	5
1.4.3 Bonding approach in bis-thiosemicarbazones	6
1.5 Transition metal complexes with thiosemicarbazone Schiff base compounds	6
1.5.1 Nickel complexes with thiosemicarbazone Schiff base compounds.....	7
1.5.2 Palladium Complexes with thiosemicarbazone Schiff base compounds	7

1.5.3	Platinum complexes with thiosemicarbazone Schiff base compounds	8
1.6	Antiproliferative activities of transition metal complexes of Schiff base compounds	9
1.7	Anti-bacterial activities of Nickel, Palladium and Platinum complexes with thiosemicarbazone Schiff base	10
1.8	Heterocyclic and thiosemicarbazone Schiff base compounds and their complexes	11
1.9	Anticancer and antibacterial activities of thiosemicarbazone and hydrazone Schiff base compounds and their complexes	14
1.10	The Problem statement	16
1.11	Objective of the research work	18
CHAPTER TWO - EXPERIMENTAL		19
2.1	Material and measurement	19
2.2	Experimental procedure for the ligands synthesis	19
2.2.1	General procedure for the synthesis of Schiff base ligands.....	19
2.2.2	Synthesis of 2-(2-hydroxy-3-methylbenzylidene)- <i>N</i> -methylhydrazine-1-carbothioamide (L1).....	22
2.2.3	Synthesis of <i>N</i> -cyclohexyl-2-(2-hydroxy-3-methylbenzylidene)hydrazine-1-carbothioamide (L2)	23
2.2.4	(<i>E</i>)- <i>N</i> -cyclohexyl-2-(2-hydroxy-5-methoxy-3-nitrobenzylidene)hydrazine-1-carbothioamide (L3).....	24
2.2.5	Synthesis of 2-(2-hydroxy-5-methoxy-3-nitrobenzylidene)- <i>N</i> -methyl hydrazine-1-carbothioamide (L4)	25
2.2.6	Synthesis of 2-(3-(tert-butyl)-2-hydroxybenzylidene)- <i>N</i> -cyclohexyl hydrazine-1-carbothioamide (L5).....	25
2.2.7	Synthesis 2-(5-(tert-butyl)-2-hydroxybenzylidene)- <i>N</i> -cyclohexylhydra zine-1-carbothioamide (L6).....	26
2.2.8	Synthesis of (<i>E</i>)- <i>N</i> -cyclohexyl-2-(3-hydroxy-4-methoxybenzylidene)hydrazine-1-carbothioamide (L7)	27

2.2.9	Synthesis of 2-methoxy-5-(((5-methylpyridin-2-yl)imino) methyl) phenol (L8).....	28
2.2.10	Synthesis of (<i>E</i>)- <i>N</i> -cyclohexyl-2-(2,4-dihydroxybenzylidene) hydra zine-1-carbothioamide (L9).....	29
2.2.11	Synthesis of 2-(3-hydroxy-4-methoxybenzylidene)- <i>N</i> -methyl hydra zine-1-carbothio amide (L10)	29
2.2.12	Synthesis of 2-methoxy-5-(((5-methylpyridin-2-yl)imino) methyl) phenol (L11).....	30
2.2.13	Synthesis of 2-methoxy-5-(((5-methylpyridin-2-yl)imino) methyl) phenol (L12).....	31
2.2.14	Synthesis of (<i>E</i>)-2-methyl-6-(((4-methylpyridin-2-yl)imino) methyl) phenol (L13).....	32
2.2.15	Synthesis of (<i>E</i>)-2-methyl-6-(((5-methylpyridin-2-yl)imino) methyl) phenol (L14).....	32
2.2.16	Synthesis of 4-methoxy-2-(((5-methylpyridin-2-yl)imino) methyl) phenol (L15).....	33
2.2.17	Synthesis of 2-methoxy-5-(((5-methylpyridin-2-yl)imino) methyl) phenol (L16).....	34
2.2.18	Synthesis of 5-(((2-(1H-benzoimidazol-2-yl)phenyl)imino) methyl)-2-met hoxyphenol (L17)	35
2.2.19	Synthesis of 5-(((4-(benzo[d]thiazol-2-yl)phenyl)imino) methyl)-2-metho xyphenol (L18)	35
2.2.20	Synthesis of 6,6'-((1 <i>E</i> ,1' <i>E</i>)-((oxybis(4,1-phenylene)) bis(azanylylid ene)) bis (methanylylidene))bi(4-methoxy-2-nitrophenol) (L19)	36
2.2.21	Synthesis of 6,6'-((1 <i>E</i> ,1' <i>E</i>)-((oxybis(4,1-phenylene))bis (azanylylid ene))bis (methanylylidene))bis(4-methoxy-2-nitrophenol) (L20)	37
2.2.22	Synthesis of 4,4'-((1 <i>E</i> ,1' <i>E</i>)-((oxybis(4,1-phenylene))bis (azanylyi dene))bis (methanylylidene))bis (benzene-1,3-diol) (L21)	38

2.3	Synthesis of Group 10 Metal Complexes	38
2.3.1	Synthesis of complex L1-Ni	42
2.3.2	Synthesis of complex L1-Pd	43
2.3.3	Synthesis of complex L1-Pt	43
2.3.4	Synthesis of complex L2-Ni	44
2.3.5	Synthesis of complex L2-Pd	45
2.3.6	Synthesis of complex L2-Pt	45
2.3.7	Synthesis of complex L3-Ni	46
2.3.8	Synthesis of complex L3-Pd	47
2.3.9	Synthesis of complex L3-Pt	47
2.3.10	Synthesis of complex L4-Ni	48
2.3.11	Synthesis of complex L4-Pd	49
2.3.12	Synthesis of complex L4-Pt	49
2.3.13	Synthesis of complex L5-Ni	50
2.3.14	Synthesis of complex L5-Pd	51
2.3.15	Synthesis of complex L5-Pt	51
2.3.16	Synthesis of complex L6-Ni	52
2.3.17	Synthesis of complex L6-Pd	53
2.3.18	Synthesis of complex L6-Pt	53
2.3.19	Synthesis of complex L7-Ni	54
2.3.20	Synthesis of complex L7-Pd	55
2.3.21	Synthesis of complex L7-Pt	55
2.3.22	Synthesis of complex L8-Ni	56
2.3.23	Synthesis of complex L8-Pd	57
2.3.24	Synthesis of complex L8-Pt	57
2.3.25	Synthesis of complex L9-Ni	58
2.3.26	Synthesis of complex L9-Pd	58

2.3.27	Synthesis of complex L9-Pt	59
2.3.28	Synthesis of complex L11(ald)-Ni	60
2.3.29	Synthesis of complex L12-Ni	60
2.3.30	Synthesis of complex L13-Ni	61
2.3.31	Synthesis of complex L14-Ni	61
2.4	Anticancer activity	62
2.4.1	<i>In vitro</i> Anticancer activity	62
2.4.2	Preparation of cell culture	62
2.4.3	MTT assay	63
2.5	Antibacterial Activity	64
2.5.1	Disc diffusion method	64
CHAPTER THREE - THE SYNTHESIS OF SCHIFF BASE LIGANDS		66
3.1	The synthesis and characterization of Schiff Base ligands	66
3.2	The Group 1 thiosemicarbazone Schiff base ligands	66
3.2.1	Analysis by FTIR spectroscopy	67
3.2.2	¹ H and ¹³ C NMR spectra	68
3.2.3	X-ray Diffraction studies of group ligands	70
3.2.3(a)	X-ray diffraction analysis of L1	70
3.2.3(b)	X-ray diffraction analysis of L2	75
3.2.3(c)	X-ray diffraction analysis of L4	76
3.2.3(d)	X-ray Diffraction analysis of L5	77
3.2.3(e)	X-ray Diffraction analysis of L6	78
3.2.3(f)	X-ray Diffraction analysis of L7	79
3.2.3(g)	X-ray Diffraction analysis of L8	80
3.2.3(h)	X-ray Diffraction analysis of L10	81
3.3	The Group 2 pyridine derivative N-heterocyclic Schiff base ligands	82

3.3.1	FTIR spectroscopy.....	83
3.3.2	¹ H and ¹³ C NMR spectra.....	83
3.3.3	X-ray diffraction analysis of Group 2 ligands	85
3.3.3(a)	X-ray Diffraction analysis of L11	85
3.3.3(b)	X-ray Diffraction analysis of L12	88
3.3.3(c)	X-ray Diffraction analysis of L14	89
3.3.3(d)	X-ray Diffraction analysis of L15	90
3.4	The Group 3 imidazole derivative Schiff base ligands	91
3.4.1	FTIR spectroscopy.....	92
3.4.2	¹ H NMR and ¹³ C NMR spectra	92
3.4.3	X-ray diffraction analysis of Group 3 ligands	94
3.4.3(a)	X-ray Diffraction analysis of L17	94
3.4.3(b)	X-ray Diffraction analysis of L18	97
3.5	The Group 4 oxybis Schiff base ligands	98
3.5.1	FTIR spectroscopy.....	98
3.5.2	¹ H and ¹³ C NMR spectra.....	99
3.5.3	Single crystal X-ray diffraction analysis of Group 4 ligands.....	101
3.5.3(a)	X-ray Diffraction analysis of L19	101
3.5.3(b)	X-ray Diffraction analysis of L20	103
3.5.3(c)	X-ray Diffraction analysis of L21	104

CHAPTER FOUR - THE COMPLEXATION OF GROUP 10

	METAL IONS WITH THE LIGANDS	106
4.1	The Synthesis and characterization of metal complexes with Schiff base ligands.....	106
4.2	The Ni(II), Pd(II) and Pt(II) complexes with ONS Schiff base ligands	106
4.2.1	FTIR spectral analysis	107

4.2.2	UV-Vis Spectroscopy	109
4.2.3	¹ H NMR and ¹³ C NMR of Complexes of L4	110
4.2.4	X-ray diffraction studies of metal complexes.....	116
4.2.4(a)	X-ray diffraction analysis of L2-Pd	116
4.2.4(b)	X-ray diffraction analysis of L3-Pd	119
4.2.4(c)	X-ray diffraction analysis of L3-Pt	123
4.2.4(d)	X-ray diffraction analysis of L4-Pt	125
4.2.4(e)	X-ray diffraction analysis of L6-Pt	128
4.3	The Ni(II), Pd(II) and Pt(II) complexes with only N and S coordination	131
4.3.1	FTIR spectra	132
4.3.2	UV-Vis Spectroscopy	133
4.3.3	¹ H NMR and ¹³ C NMR of L7-Pd and L7-Pt	134
4.3.4	X-ray diffraction analysis of L7-Ni	140
4.4	The Ni(II) complexes of Group 2 with N, N and O coordination	144
4.4.1	FTIR spectra	145
4.4.2	UV-Vis Spectroscopy	146
4.4.3	X-ray diffraction analysis of L11(ald)-Ni	147
CHAPTER FIVE - BIOLOGICAL ACTIVITY		151
5.1	Anticancer activity	151
5.1.1	The anticancer activity of L4 and L4-Ni , L4-Pd and L4-Pt	151
5.1.2	The anticancer activity of the synthesized ligand L7 and L7-Ni , L7-Pd and L7-Pt	162
5.1.3	The anticancer activity of Schiff base compounds L15-L18	170

5.1.4	Molecular Binding Studies of highest potential L7-Ni with tyrosine kinase	178
5.1.5	Summary for the anticancer study	181
5.2	Antibacterial activity of some of the compounds synthesized in this study	183
5.2.1	The antimicrobial activity against <i>Escherichia coli</i> and <i>Staphylococcus aureus</i>	184
5.2.2	The summary of the antibacterial activity study.....	191
CHAPTER SIX - CONCLUSION		192
6.1	Conclusion	192
6.2	Recommendation for Future Study	195
REFERENCES		196
APPENDICES		
LIST OF PUBLICATIONS AND CONFERENCE PRESENTATIONS		

LIST OF TABLES

		Page
Table 2.1	Ligand labels and their identity for compounds in Scheme 2.1	20
Table 2.2	Ligand labels and their identity for compounds in Scheme 2.2	21
Table 2.3	Ligand labels and their identity for compounds in Scheme 2.3	21
Table 2.4	Ligand labels and their identity for compounds in Scheme 2.4	22
Table 2.5	Complex labels and their identity for compounds in Scheme 2.5	39
Table 2.6	Complex labels and their identity for compounds in Scheme 2.6	40
Table 2.7	Complex labels and their identity for compounds in Scheme 2.7 and 2.8	41
Table 2.8	Complex labels and their identity for compounds in Scheme 2.9	42
Table 3.1	Crystal data and refinement parameters of Group 1 ligands L1 , L2 , L4 , L5 , L6 , L7 , L8 and L10 . The crystal structure of L3 and L9 could not be determined	72
Table 3.2	Crystal data and refinement parameters of Group 2 ligands L11 , L12 , L14 and L15	86
Table 3.3	Crystal data and refinement parameters of Group 3 ligands L17 and L18	95
Table 3.4	Crystal data and refinement parameters of Group 4 ligands L19 , L20 and L21	102
Table 4.1	Crystal data and refinement parameters of L2-Pd	118
Table 4.2	Crystal data and refinement parameters of L3-Pd and L3-Pt	121
Table 4.3	Significant bond length (Å) and bond angle (°) of L3-Pd	122
Table 4.4	Significant bond length (Å) and bond angle (°) of L3-Pt	124
Table 4.5	Crystal data and refinement parameters of L4-Pt	126
Table 4.6	Significant bond length (Å) and bond angle (°) of L4-Pt	127
Table 4.7	Crystal data and refinement parameters of L6-Pt	130

Table 4.8	Crystal data and refinement parameters of L7-Ni	142
Table 4.9	Significant bond length (Å) and bond angle (°) of L7-Ni	143
Table 4.10	Crystal data and refinement parameters of L11(ald)-Ni	149
Table 4.11	Significant bond length (Å) and bond angle (°) of L11(ald)-Ni	150
Table 5.1	The IC ₅₀ (µM) and SI values of the synthesized compounds and standard drugs towards HCT 116, Hela, MCF-7 and Eahy926 cell lines.....	154
Table 5.2	The IC ₅₀ (µM) and SI values of the compounds L7 , L7-Ni , L7-Pd and L7-Pt and standard drug against HCT 116, Hela andEa.hy926 cell lines.....	164
Table 5.3	The IC ₅₀ (µM) and SI values for the compounds and standard drugtested on HCT 116, MCF-7 and Ea.hy926 cell lines.....	172
Table 5.4	Type of Interactions established by L7-Ni with the respective amino acids at the active site of tyrosine kinase	181
Table 5.5	Antimicrobial activity of the ligand L2 and its complexes with Ni(II), Pd(II) and Pt(II) against <i>E. coli</i> and <i>S. aureus</i> bacteria.....	185
Table 5.6	Antimicrobial activity of the ligand L3 and its complexes with Ni(II), Pd(II) and Pt(II) against <i>E. coli</i> and <i>S. aureus</i> bacteria.....	186
Table 5.7	Antimicrobial activity of the ligand L6 and its complexes with Ni(II), Pd(II) and Pt(II) against <i>E. coli</i> and <i>S. aureus</i> bacteria.....	188
Table 5.8	Antimicrobial activity of the ligand L9 and its complexes withNi(II), Pd(II) and Pt(II) against <i>E. coli</i> and <i>S. aureus</i> bacteria.....	189
Table 5.9	Antimicrobial activity of the compounds L19 - L21 against <i>E. coli</i> and <i>S. aureus</i> bacteria	190

LIST OF FIGURES

	Page
Figure 3.2	The FTIR spectrum of the parent aldehyde and the resulting Schiff base ligand L468
Figure 3.2	The ¹ H NMR spectrum of ligand L469
Figure 3.3	The ¹³ C NMR spectrum of ligand L469
Figure 3.4	The ORTEP diagram of the crystal structure of L171
Figure 3.5	The ORTEP diagram of the crystal structure of L275
Figure 3.6	The ORTEP diagram of the crystal structure of L476
Figure 3.7	The ORTEP diagram of the crystal structure of L577
Figure 3.8	The ORTEP diagram of the crystal structure of L678
Figure 3.9	The ORTEP diagram of L7 in individual form79
Figure 3.10	The ORTEP diagram of L7 in stacking form80
Figure 3.11	The ORTEP diagram of the crystal structure of L881
Figure 3.12	The ORTEP diagram of the crystal structure of L1082
Figure 3.13	The FTIR spectrum of the parent aldehyde and the resulting ligand (L14)83
Figure 3.14	The ¹ H NMR spectrum of ligand L1484
Figure 3.15	The ¹³ C NMR spectrum of ligand L1485
Figure 3.16	The ORTEP diagram of the crystal structure of L1186
Figure 3.17	The ORTEP diagram of the crystal structure of L1289
Figure 3.18	The ORTEP diagram of the crystal structure of L1490
Figure 3.19	The ORTEP diagram of the crystal structure of L1591
Figure 3.20	The FTIR spectrum of the parent aldehyde and the resulting ligand L1892

Figure 3.21	The ¹ H NMR spectrum of ligand L18	93
Figure 3.22	The ¹³ C NMR spectrum of ligand L18	94
Figure 3.23	The ORTEP diagram of the crystal structure of L17	95
Figure 3.24	The ORTEP diagram of the crystal structure of L18	97
Figure 3.25	The FTIR spectrum of the parent aldehyde and the resulting ligand (L20).....	99
Figure 3.26	The ¹ H NMR spectrum of ligand L20	100
Figure 3.27	The ¹³ C NMR spectrum of ligand L20	100
Figure 3.28	The ORTEP diagram of the crystal structure of L19	101
Figure 3.29	The ORTEP diagram of the crystal structure of L20	104
Figure 3.30	The ORTEP diagram of the crystal structure of L21	105
Figure 4.1	The FTIR spectrum of L4 and its complexes L4-Ni , L4-Pd and L4-Pt	108
Figure 4.2	The FTIR spectrum L6 and its complexes L6-Ni , L6-Pd and L6-Pt	109
Figure 4.3	The UV- Vis spectroscopy (a) L4 , (b) L4-Ni , (c) L4-Pd and (d) L4-Pt	110
Figure 4.4	The ¹ H NMR spectrum of L4-Pd	112
Figure 4.5	The ¹ H NMR spectrum of L4-Pt	113
Figure 4.6	The ¹³ C NMR spectrum of L4-Pd	115
Figure 4.7	The ¹³ C NMR spectrum of L4-Pt	115
Figure 4.8	The skeletal octahedral Pd ₄ S ₄ core structure in L2-Pd crystal.....	117
Figure 4.9	The ORTEP diagram of L2-Pd showing the heteroatoms bonded to the Pd atoms. The labelling of the carbon and hydrogen atoms have been omitted for clarity	118
Figure 4.10	The ORTEP diagram of L3-Pd	120
Figure 4.11	The ORTEP diagram of L3-Pt	124
Figure 4.12	The ORTEP diagram of L4-Pt	126

Figure 4.13	The ORTEP diagram of L6-Pt	129
Figure 4.14	The FTIR spectrum of L7 and its complexes L7-Ni , L7-Pd and L7-Pt	133
Figure 4.15	The UV- Vis spectrum (a) L7 , (b) L7-Ni , (c) L7-Pd and (d) L7-Pt	134
Figure 4.16	The ¹ H NMR spectra of ligand L7	135
Figure 4.17	The ¹ H NMR spectrum of L7-Pd	136
Figure 4.18	The ¹ H NMR spectra of L7-Pt	137
Figure 4.19	The ¹³ C NMR spectra of ligand L7	138
Figure 4.20	The ¹³ C NMR spectrum of L7-Pd	139
Figure 4.21	The ¹³ C NMR spectrum of L7-Pt	139
Figure 4.22	The ORTEP diagram of L7-Ni	140
Figure 4.23	The packing structure of L7-Ni showing the inter and intra molecular hydrogen bonding.....	141
Figure 4.24	The FTIR spectra of the ligands L11 and L14 and their complexes L11(ald)-Ni and L14-Ni	146
Figure 4.25	The UV- Vis spectrum (a) L11 , (b) L14 , (c) L14-Ni and (d) L11(ald)-Ni	147
Figure 4.26	The ORTEP diagram of L11(ald)-Ni	148
Figure 5.1	Photomicrographic images of human colorectal carcinoma (HCT 116) were taken at 48 hours of treatment under an inverted microscope at × 40 magnification with a digital camera: (A) Negative control (0.1% DMSO), (B) Standard drug, 5-Fluorouracil, (C) Compound L4 , (D) Compound L4- Ni , (E) Compound L4-Pd and (F) Compound L4-Pt . The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating HCT 116 cells. (G) The graphical representation of the dose-dependent antiproliferative effect of the compounds L4 , L4-Ni , L4-Pd and L4-Pt on HCT 116 cells.....	156
Figure 5.2	Photomicrographic images of human cervical carcinoma (Hela) were taken at 48 hours of treatment under an inverted microscope at × 40 magnification with a digital camera: (A) Negative control ((0.1% DMSO), (B) Standard drug, Betulinic acid, (C) Compound L4 , (D) Compound L4-Ni , (E)	

Compound **L4-Pd** and (F) Compound **L4-Pt**. The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating Hela. (G) The graphical representation of the dose-dependent antiproliferative effect of compounds **L4**, **L4-Ni**, **L4-Pd** and **L4-Pt** on Hela cell158

Figure 5.3 Photomicrographic images of human breast adenocarcinoma (MCF-7) were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO), (B) Standard drug, Tamoxifen, (C) Compound **L4**, (D) Compound **L4-Ni**, (E) Compound **L4-Pd** and (F) Compound **L4-Pt**. The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating MCF-7 cells. (G) The graphical representation of the antiproliferative effect of compounds **L4**, **L4-Ni**, **L4-Pd** and **L4-Pt** on MCF-7 cells.....160

Figure 5.4 Photomicrographic images of human endothelial hybrid (Ea.hy926) cell were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO) (B) Standard drug, H₂O₂, (C) Compound **L4**, (D) Compound **L4-Ni**, (E) Compound **L4-Pd** and (F) Compound **L4-Pt**. The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating Ea.hy926 cells. (G) The graphical representation of the antiproliferative effect of compounds **L4**, **L4-Ni**, **L4-Pd** and **L4-Pt** on Ea.hy926cells162

Figure 5.5 Photomicrographic images of human colorectal carcinoma (HCT 116) were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO), (B) Standard drug, Cisplatin, (C) Compound **L7**, (D) Compound **L7-Ni**, (E) Compound **L7-Pd** and (F) Compound **L7-Pt**. The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating HCT 116 cells. However, the cells treated with the standard reference cisplatin and **L7-Ni** (IC₅₀ = 10.1 and 7.9 μ M, respectively) demonstrated significant ($p < 0.01$) inhibitory effect on the proliferation of the cells. (G) The graphical representation of the antiproliferative effect of **L7**, **L7-Ni**, **L7-Pd** and **L7-Pt** on HCT 116 cells.....166

Figure 5.6 Photomicrographic images of human cervical carcinoma (Hela) were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO) (B) Standard drug, Betulenlic acid, (C) Compound **L7**, (D) Compound **L7-Ni**, (E) Compound **L7-Pd** and (F) Compound **L7-Pt**. The cell group treated with vehicle (0.1% DMSO) was displayed fully confluent compact monolayer of proliferating Hela cells. (G) The graphical representation of the antiproliferative

	effect of compounds L7 , L7-Ni , L7-Pd and L7-Pt on Hela cells	168
Figure 5.7	Photomicrographic images of Human endothelial hybrid (Ea.hy926) cell were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO) (B) Standard drug, H ₂ O ₂ , (C) Compound L7 , (D) Compound L7-Ni , (E) Compound L7-Pd and (F) Compound L7-Pt . The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating Ea.hy926 cells. (G) The graphical representation of the antiproliferative effect of compounds L7 , L7-Ni , L7-Pd and L7-Pt on Ea.hy 926cells	170
Figure 5.8	Photomicrographic images of human colorectal carcinoma (HCT 116) were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO), (B) Standard drug, 5- Fluorouracil, (C) Compound L17 , (D) Compound L18 , (E) Compound L15 and (F) Compound L16 . The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating HCT 116 cells. (G) The graphical representation of the dose-dependent antiproliferative effect of compounds L15 -L18 on HCT 116 cells.....	174
Figure 5.9	Photomicrographic images of human breast adenocarcinoma (MCF-7) were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO), (B) Standard drug, Tamoxifen, (C) Compound L17 , (D) Compound L18 , (E) Compound L15 and (F) Compound L16 . The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating MCF-7 cells. (G) The graphical representation of the dose - dependent antiproliferative effect of compounds L15-L18 on MCF-7 cells	176
Figure 5.10	Photomicrographic images of Human endothelial hybrid (Ea.hy926) cell were taken at 48 hours of treatment under an inverted microscope at $\times 40$ magnification with a digital camera: (A) Negative control (0.1% DMSO), (B) Standard drug, H ₂ O ₂ , (C) Compound L17 , (D) Compound L18 , (E) Compound L15 and (F) Compound L16 . The cell group treated with 0.1% DMSO was displayed fully confluent compact monolayer of proliferating Ea.hy926 cells. (G) The graphical representation of the dose- dependent antiproliferative effect of compounds L15-L18 on Ea.hy926 cells.....	178
Figure 5.11	Binding mode of L7-Ni at the active site of tyrosine kinase (PDB ID 1t46)	179

Figure 5.12	Binding mode of compound L7-Ni at the active site of tyrosine kinase (PDB ID 1t46) showing two hydrogen bonding with Glu64 and Thr670	180
Figure 5.13	The inhibition zone of L2 and its Ni(II), Pd(II) and Pt(II) complexes against <i>S. aureus</i> and <i>E. coli</i>	186
Figure 5.14	The inhibition zone of L3 and its Ni(II), Pd(II) and Pt(II) complexes against <i>S. aureus</i> and <i>E. coli</i>	187
Figure 5.15	The inhibition zone of L6 and its Ni(II), Pd(II) and Pt(II) complexes against <i>S. aureus</i> and <i>E. coli</i>	188
Figure 5.16	The inhibition zone of L9 and its Ni(II), Pd(II) and Pt(II) complexes against <i>S. aureus</i> and <i>E. coli</i>	189
Figure 5.17	The inhibition zone of L19 , L20 and L21 against <i>S. aureus</i> and <i>E. coli</i>	191

LIST OF SCHEMES

	Page
Scheme 1.1	The chemical reaction to show the synthesis of a Schiff base 1
Scheme 1.2	The structure of heterocyclic Schiff base compounds..... 2
Scheme 1.3	The structure of different type of carbazones..... 3
Scheme 1.4	The structure of thiosemicarbazone Schiff base compounds 3
Scheme 1.5	Bis-thiosemicarbazone Schiff base compounds 4
Scheme 1.6	The possible molecular forms of thiosemicarbazones in a solution neutral thione (1a), neutral thiol (1b) and anionic (1c)..... 4
Scheme 1.7	The coordination and bridging modes of neutral thiosemicarbazones ligands to metals 5
Scheme 1.8	The coordination mode of anionic thiosemicarbazone ligands to metals 6
Scheme 1.9	The coordination mode of bis-thiosemicarbazone ligands to metals..... 6
Scheme 1.10	The possible bonding to metal and hydrogen bonding..... 10
Scheme 1.11	The square planer Ni(II) complexes of thiosemicarbazone Schiff base ligands..... 11
Scheme 1.12	The synthesized complexes of thiosemicarbazone Schiff base ligand to nickel 13
Scheme 1.13	The synthesized complexes of thiosemicarbazone Schiff base ligand to palladium..... 13
Scheme 1.14	The synthesized complexes of thiosemicarbazones Schiff base ligand to platinum..... 14
Scheme 2.1	Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and carbothioamide derivatives..... 20
Scheme 2.2	Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and pyridine derivatives 21

Scheme 2.3	Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and imidazole derivatives.....	21
Scheme 2.4	Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and 4,4'-oxydianiline	22
Scheme 2.5	Complexation of Ni(II) and Pd(II) with Schiff base ligands. The scheme shows the reaction between carbothioamide derivative Schiff base and nickel and palladium acetate salts in alkaline medium	39
Scheme 2.6	Complexation of Pt(II) with Schiff base ligands. The reaction scheme shows the reaction between carbothioamide derivative Schiff base and potassium tetrachloroplatinate salt in alkaline medium	40
Scheme 2.7	Complexation of Ni(II) and Pd(II) with Schiff base ligand. The scheme shows the reaction between carbothioamide derivative Schiff base and nickel and palladium acetate salt in alkaline medium	41
Scheme 2.8	Complexation of Pt(II) with Schiff base ligand. The scheme shows the reaction between carbothioamide derivative Schiff base and nickel and palladium acetate salt in alkaline medium	41
Scheme 2.9	Complexation of Ni(II) Schiff base ligands. The scheme shows the reaction between heterocyclic phenolic Schiff base and nickel and palladium acetate.....	42
Scheme 3.1	Synthesis of Schiff base ligand L4 . The scheme shows the reaction of 2-hydroxy-5-methoxy-3-nitrobenzaldehyde and <i>N</i> -methylhydrazinecarbothioamide. (See Table 2.1 for other substituent details)	67
Scheme 3.2	Synthesis of Schiff base ligand L14 . The scheme shows the reaction between 2-hydroxy-3-methylbenzaldehyde and 5-methylpyridin-2-amine	82
Scheme 3.3	Synthesis of the Schiff base ligand L18 . The scheme shows the reaction between 3-hydroxy-4-methoxybenzaldehyde and 2-(benzo[d]thiazol-2-yl)aniline.....	91
Scheme 3.4	Synthesis of the Schiff base ligand L20 . The scheme shows the reaction between 2-hydroxy-3-methylbenzaldehyde and 4,4'-oxydianiline	98
Scheme 4.1	Complexation of Ni(II) and Pd(II) with Schiff base ligand L4 . The scheme shows the reaction between (<i>E</i>)-2-(2-hydroxy-5-methoxy-3-nitro benzylidene)- <i>N</i> -methylhydrazine-1-carbothioamide (L4) and Ni(II) acetate and Pd(II) acetate salts in alkaline medium	107

Scheme 4.2	Complexation of Pt(II) with Schiff base ligand L4 . The reaction scheme shows the reaction between (<i>E</i>)-2-(2-hydroxy-5-methoxy-3-nitrobenzylidene)- <i>N</i> -methylhydrazine-1-carbothioamide (L4) and Pt(II) salt in DMSO in alkaline medium 107	107
Scheme 4.3	Complexation of Ni(II) and Pd(II) with Schiff base ligand L7 (in a 2:1 ratio). The scheme shows the reaction between L7 and Ni(II) acetate and Pd(II) acetate salt in alkaline medium 132	132
Scheme 4.4	Complexation of Pt(II) with Schiff base ligand (in a 1:1 ratio). The scheme shows the reaction between L7 and Pt(II) in DMSO solvent in alkaline medium 132	132
Scheme 4.5	Complexation of Ni(II) Schiff base ligands. The scheme shows the reaction between (<i>E</i>)-2-methyl-6-(((4-methylpyridin-2-yl)imino)methyl)phenol and the Ni(II) acetate forming the L14-Ni ... 144	144
Scheme 4.6	Complexation of Ni(II) Schiff base ligands. The scheme shows the reaction between (<i>E</i>)-4-methyl-2-(((4-methylpyridin-2-yl)imino)methyl)phenol and the Ni(II) acetate forming the truncated complex L11(ald)-Ni 145	145

LIST OF ABBREVIATIONS AND SYMBOLS

Å	Angstrom
Anal. Cal.	Analytical Calculation
Ar	Argon
aro	Aromatic
atm	Atmosphere
BPS	Phosphate Buffered Saline
cm ⁻¹	Wavenumber
¹³ C NMR	Carbon-13 Nuclear magnetic resonance
Cy	Cyclohexyl
DMSO	Dimethyl Sulfoxide
DNA	Deoxyribonucleic acid
d	Doublet
d ₆	Deuterated Solvent
DMF	Di-methylformamide
DCM	Di-chloromethane
Ea.hy926	endothelial normal cell lines
EtOH	Ethanol

<i>E. coli</i>	<i>Escherichia coli</i>
FTIR	Fourier-transform infrared spectroscopy
FBS	Fetal Bovine Serum
g	gram
h	Hour
Hz	Hertz
¹ H NMR	Hydrogen -1 Nuclear magnetic resonance
Hela	Cervical carcinoma cell lines
HCT 116	Human colorectal carcinoma cell lines
IC ₅₀	Inhibitory concentration (dose causing 50% inhibition of cell growth)
i.e.	That is
K ₂ PtCl ₄	Potassium tetrachloroplatinate
L	Liter
LMS	Least Mean Square
MeOH	Methanol
MCF-7	Breast cancer cells
MIC	Minimum Inhibition Concentration
mL	Mililiter

mmol	millimole
mol	Mole
MTT	(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
NaOH	Sodium Hydroxide
Ni(II)	Nickel ion
Ni(OAc) ₂ ·4H ₂ O	Nickel(II) acetate tetrahydrate
nm	nanometer
OAc	acetate
Pd(OAc) ₂	Palladium acetate
Pd(II)	Palladium ion
Pt(II)	Platinum ion
Pyr	Pyridine
q	quartet
rmp	Rotation Per Minute
s	singlet
<i>S. aureus</i>	<i>Staphylococcus aureus</i>
SI	Selectivity Index
t	triplet

TSC	Thiosemicarbazone
THF	Tetrahydrofuran
°	degree
°C	Degree Celsius (degree centigrade)
μL	microliter
λ	Wavelength
δ	chemical shift
%	percentage

**SINTESIS KOMPLEKS SCHIFF BES LOGAM KUMPULAN 10 YANG
MENGANDUNGI ONN DAN ONS: PENCIRIAN SERTA AKTIVITI
SITOTOKSISITI DAN ANTIBAKTERIA**

ABSTRAK

Dua puluh satu ligan bes Schiff daripada terbitan salisildihida yang mempunyai amina heterosiklik, anilina dan karbotioamida telah disintesis. Ligan telah dikoordinasikan dengan logam peralihan Kumpulan 10 seperti Ni(II), Pd(II) dan Pt(II). Sebatian yang telah disintesis telah dicirikan dengan parameter fizikal seperti takat lebur dan analisis unsur bahan. Sebatian ini juga telah dicirikan dengan teknik spektroskopi, i.e. FTIR, ^1H NMR, ^{13}C NMR, dan UV-Vis. Kebanyakan struktur ligan telah ditentukan dengan analisis pembelauan sinar-X kristal tunggal. Ligan poli dentat yang mengandungi kumpulan ONS dan ONN dikoordinatkan melalui kumpulan nitrogen imina, oksigen fenolik dan sulfur tiolat untuk membentuk kompleks planar persegi. Ligan tersebut membentuk kompleks satah segiempat sama dan oktahedron dengan ion Ni(II). Kompleks gugusan satah segiempat sama dan tetra-palladat diperoleh melalui koordinasi kumpulan ONS bersama Pd(II). Kompleks dan kompleks makro telah diperoleh melalui koordinasi Pt(II) dengan ligan yang mengandungi kumpulan ONS. Aktiviti biologi telah dinilai untuk potensi antikanser terhadap tiga jenis sel kanser iaitu kanser payudara manusia (MCF-7), kanser serviks (Hela), dan kanser kolon (HCT 116). Kompleks logam telah mempamerkan aktiviti yang lebih tinggi berbanding ligan sahaja terhadap semua jenis sel. Di dalam kebanyakan siri, kompleks Ni(II) telah menunjukkan aktiviti yang lebih tinggi berbanding kompleks Pd(II) dan Pt(II). Di antara sebatian yang telah disintesis, aktiviti tertinggi telah

ditunjukkan oleh **L7-Ni** terhadap karsinoma kolorektal dengan $IC_{50} = 7.90 \pm 0.40 \mu\text{M}$, sedangkan piawai cisplatin menunjukkan $IC_{50} = 10.1 \pm 1.00 \mu\text{M}$. Beberapa kompleks menunjukkan aktiviti yang sama seperti ubat yang sedia ada. Pada umumnya, kompleks logam mempamerkan aktiviti yang lebih tinggi daripada ligan. Secara umum semua ligan didapati tidak toksik terhadap sel-sel normal manusia (sel endotelial manusia Ea.hy926). Beberapa kompleks logam didapati toksik kepada sel-sel manusia biasa, contohnya IC_{50} **L2-Pt** dan **L3-Ni** masing-masing adalah $16.30 \pm 0.90 \mu\text{M}$ dan $5.80 \pm 0.10 \mu\text{M}$. Potensi antibakteria beberapa ligan terpilih dan kompleksnya diuji untuk sifat antibakteria terhadap dua jenis bakteria, iaitu *Escherichia coli* (Gram-negative, ATCC 25922), dan *Staphylococcus aureus* (Gram-positif, ATCC 12600) melalui kaedah penyebaran cakera menggunakan antibiotik piawai. Di antara ligan dan kompleks yang diuji, beberapa daripadanya didapati aktif terhadap bakteria. Walau bagaimanapun, kompleks logam menunjukkan aktiviti yang lebih tinggi daripada ligan. Secara umumnya, kompleks Ni(II) dan Pd(II) mempamerkan aktiviti yang lebih tinggi daripada kompleks Pt(II).

**THE SYNTHESIS OF GROUP 10 METALS SCHIFF BASE COMPLEXES
WITH ONN AND ONS GROUPS: CHARACTERIZATION AND THEIR
CYTOTOXICITY AND ANTIBACTERIAL ACTIVITIES**

ABSTRACT

Twenty-one Schiff base ligands of salicyldehyde derivatives with heterocyclic amine, aniline and carbothioamide were synthesized. The ligands were coordinated to Group 10 transition metals Ni(II), Pd(II) and Pt(II). The synthesized compounds were characterized with physical parameters such as melting point and elemental analysis. These compounds were further characterized with spectroscopic techniques, i.e. FTIR, ^1H NMR, ^{13}C NMR, and UV-visible spectroscopy. The structure of most of the ligands were elucidated with single crystal X-ray diffraction analysis. The poly dentate ONS and ONN group containing ligands coordinated via imine nitrogen, phenolic oxygen and thiolate sulphur to form square planar complexes. The ligands form square planar and octahedral complexes with Ni(II). Square planar and tetra-palladate cluster complexes were obtained with Pd(II) with the ligands containing the ONS group. Square planar and macro complexes were obtained with Pt(II) and ONS group containing ligands. The biological activity was evaluated for their anticancer properties against three human breast cancer (MCF-7), cervical cancer (Hela), and colon cancer (HCT 116) cell lines. The complexes exhibited higher activity than ligands on all the cell types. In most of the series the Ni(II) complexes showed higher activity than Pd(II) and Pt(II). The **L7-Ni** showed highest activity against colorectal carcinoma with $\text{IC}_{50} = .90 \pm 0.40 \mu\text{M}$ among the synthesized compounds, whereas standard cisplatin shows $\text{IC}_{50} = 10.1 \pm 1.00 \mu\text{M}$. A few of the complexes showed very


similar activity as standard existing drugs. Generally, the metal complexes exhibited higher activity than the ligands. In general all the ligands were found to be non-toxic to normal human cell line (human endothelial cell line Ea.hy926). Some metal complexes were found to be toxic to the normal human cell line, e.g. the IC₅₀ of **L2-Pt** and **L3-Ni** is $16.30 \pm 0.90 \mu\text{M}$ and $5.80 \pm 0.10 \mu\text{M}$ respectively. The antibacterial activities of a few selective ligands and their complexes were tested for their antibacterial properties against two bacteria, i.e. *Escherichia coli* (Gram-negative, ATCC 25922), and *Staphylococcus aureus* (Gram-positive, ATCC 12600) via disc diffusion method using the standard antibiotic. Among the tested ligands and complexes a few of them were found active against bacteria. However, the metal complexes showed higher activity than ligands. Generally, the Ni(II) and Pd(II) complexes exhibited a higher activity than Pt(II) complexes.

CHAPTER ONE

INTRODUCTION

1.1 Schiff Base Compounds

Schiff base compounds are an important class of chemicals in this modern age of chemistry. Hugo Schiff was known as the first chemist who reported these compounds in 1864 [1]. Schiff bases are known as imines or azomethine compounds [1-5], generally having the formula $R_1R_2C=NR_3$ (Scheme 1.1), whereas R_1 , R_2 and R_3 are alkyl, aryl, hydrogen or heteroaryl groups [1, 5, 6]. The Schiff base compounds and their coordination complexes with transitional metals has played a significant role in coordination chemistry, polymer chemistry, material science, medicinal and industrial chemistry [7-11]. Azomethine compounds having important C=N linkage show potential antibacterial, anticancer, antifungal and antidiuretic activities [3, 12-15].




Scheme 1.1. The chemical reaction to show the synthesis of a Schiff base.

1.2 N-heterocyclic Schiff base compounds

Heterocyclic Schiff base compounds having heteroatoms S, N and O (Scheme 1.2) show a wide variety of biological activity as well as show distinct chemical characteristics due to their diversity in bonding to transition metals [16-19]. Nitrogen and sulphur containing heterocyclic pyridine and thiazole moieties show potential

biological activities against hyperthyroidism, human immunodeficiency virus (HIV), fungal, prion disease and gram-positive and gram-negative bacteria [20-22]. Imidazoles are potential biomolecules which show interesting biological activities such as antimicrobial, anti-candida, anti-tumor, anti-cancer, anti-inflammatory, cytotoxicity and anti-cryptococcal, like histidine, histamine and purine amino acids [23-26].




Scheme 1.2. The structure of heterocyclic Schiff base compounds.

1.3 Type of carbazone Schiff base compounds

Schiff bases of isothiosemi-, thiosemi-, and semicarbazone (Scheme 1.3), have been well studied due to their wide biological application, particularly their anti-cancer and anti-bacteria activities [27-33]. The interest in Schiff bases gradually increased due to the presence of hard or soft Lewis bases atoms together in the same molecule. The thiosemicarbazone Schiff base compounds contain soft Lewis base such as sulphur and nitrogen coordinating atoms as well as the hard Lewis base, oxygen atom


[34]. These Schiff base compounds are of special interest because of their diversity in hard and soft Lewis base metal complexation with hard and soft coordinating sites NSO [34-39].



Scheme 1.3. The structure of different type of carbazones.

1.3.1 Mono-thiosemicarbazone

Mono-thiosemicarbazone ($\text{R}^1\text{R}^2\text{C}^2=\text{N}^3-\text{N}^2(\text{H})-\text{C}^1(=\text{S})\text{N}^1\text{R}^3\text{R}^4$) **1** (Scheme 1.4) compounds have different subclasses, determined by the substituents R^1 , R^2 , R^3 and R^4 . The compound which originated from aldehyde, i.e. one of two substituents of C^2 (R^1 , R^2) is hydrogen and the substituents in N^1 (R^3 , R^4) both can be hydrogen or one hydrogen and secondly the alkyl or aryl.




Scheme 1.4. The structure of thiosemicarbazone Schiff base compounds.

1.3.2 Bis-thiosemicarbazones

Bis-thiosemicarbazones are formed by connecting to separated thiosemicarbazones moieties connected via a ring or C-C bond, as shown in structures **2** and **3**, respectively (Scheme 1.5). These tetra-dentate ligands entrap metal inside to form square planar complexes [40-42]. The length of the C-C bond in the backbone



affects the stability of the complexes. The higher number of C-C bonds via alkylation or arylation allow to better fit metal ions inside of the ligand cavity [41]. These tetradentate ligands and transition metal complexes exhibit promising anticancer and antibacterial activity [43].



Scheme 1.5. Bis-thiosemicarbazone Schiff base compounds.

1.4 Different molecular forms of thiosemicarbazones Schiff base compounds


Thiosemicarbazone can exist as thione-thiol tautomers **1a-1b** (Scheme 1.6) and both tautomers can coordinate to a metal centre. The anionic **1c** forms (Scheme 1.6) due to deprotonation of N^2H (**1a**) or SH (**1b**) [43]. There are different bonding modes of neutral and anionic forms according to substituent and central metal ion [44, 45].



Scheme 1.6. The possible molecular forms of thiosemicarbazones in a solution neutral thione (**1a**), neutral thiol (**1b**) and anionic (**1c**).

1.4.1 Bonding approach in neutral form


The thiosemicarbazone ligand series ($R^1R^2C^2=N^3-N^2(H)-C^1(=S)N^1R^3R^4$) are coordinated to metal in neutral form, **1a** through the lone pair electrons of nitrogen atom (N^3) and S-chelation with X-bridging ($X = N$ or O). The coordination occurs through only the S atom are also known as shown in **4-5** (Scheme 1.7) [46, 47] and the lone pair electrons of N^3 and S-chelation in **6** [48] of N^3 and S-chelation in **7** [47, 49]. The other bonding modes are via X, N^3 and S chelation in **8** [50, 51] and X, N^3 and S chelation with S-bridging in **9** [52]. X bridging mode with S, N^3 and X chelation in **10** (Scheme 1.7) are also observed [53].



Scheme 1.7. The coordination and bridging modes of neutral thiosemicarbazones ligands to metals.

1.4.2 Bonding approach in anionic form


The thiosemicarbazone series ($R^1R^2C^2=N^3-N^2(H)-C^1(=S)N^1R^3R^4$) in the anionic form **1c** (Scheme 1.6) coordinate in different modes with metals as shown in **8-10** (Scheme 1.7) via N^3 , S-chelation and X-bridging as well as N^3 , S-chelation and S-bridging (where $X = N$ or O). In the anionic form, the ligand will coordinate with metals via N^2 and S chelation as shown in **11**, whereas N^2 and S chelation and S bridging in **12** (Scheme 1.8) [54-60].



Scheme 1.8. The coordination mode of anionic thiosemicarbazone ligands to metals.

1.4.3 Bonding approach in bis-thiosemicarbazones

The bis-thiosemicarbazones can coordinate either in the anionic or in the neutral form via both wings. The specific approach depends on the central ring; the connections are shown in **13** and **14** (Scheme 1.9) [61-63]. The bis-thiosemicarbazone undergoes deprotonation at the NH group and the tetra-dentate N_2S_2 subsequently coordinates to metal ions forming square planar complexes [64, 65]. The bis-thiosemicarbazone chelating ligand form polynuclear complexes with different binding modes via N and S coordinating sites [66].



Scheme 1.9. The coordination mode of bis-thiosemicarbazone ligands to metals.

1.5 Transition metal complexes with thiosemicarbazone Schiff base compounds

Thiosemicarbazones having ONS coordinating sites are important in coordination chemistry due to their strong bonding ability with transition metals. These Schiff base compounds are of special interest because of their diversity in coordinating to hard and soft metals using the hard and soft coordinating sites. These compounds

and their complexes with transition metals have wide biological and pharmaceutical applications.

1.5.1 Nickel complexes with thiosemicarbazone Schiff base compounds

Schiff base containing thiosemicarbazone moieties and their metal complexes have significant interest because of their potential in biological activity [67]. The Ni(II) complexes with Schiff base ligands having dithiocarbazate moiety have been noted to exhibit strong activities against lymphocytic leukaemia [68]. The NS donor Schiff base ligand having thiodipropanoic acid and antipyrine moieties coordinated to Ni(II) have shown potential antifungal and antibacterial activities [69]. The Ni(II) complexes with tetradentate N₂O₂ and tridentate N₂O Schiff base ligands were significantly studied for catalytic and biological activity [70-72]. The Ni(II) complexes with (Z)-2-hydroxy-N'-(2-oxoindolin-3-ylidene) benzohydrazide and similar ligands have shown potential antimicrobial, antitumor and anti-cancer activities compared to the free ligand [13, 72, 73]. The NSO coordinating site containing thiosemicarbazone ligand forming complexes with Ni(II) exhibit more antibacterial, anticancer and anticancer activity than the free ligand [74, 75].

1.5.2 Palladium Complexes with thiosemicarbazone Schiff base compounds

The thiosemicarbazones and dithiocarbazide with N and S donor site are known as soft Lewis base, thus theoretically strongly coordinated with soft Lewis acid such as palladium Pd(II) [76, 77]. The Pd(II) is d^8 metal ion, can form stable complexes with S containing thiosemicarbazone ligand due to strong σ -bond and d_{π} - d_{π} bonds by the donation of an electron pair to the ligand [30]. These Pd(II) complexes are more potent against virus such as malaria, tumour, cancer cells, bacteria, and fungi by

inhibiting their ribonucleotide and transforming it to the deoxy-ribonucleotide [77-79]. Square planar complexes of palladium with Schiff base containing nitrogen and oxygen/sulphur coordinating sites are very important systems on account of their anticancer, catalytic and antitumor activities [80]. The Pd(II) complexes with nitrogen containing pyridine, quinoline, derivatives ligands shown promising anticancer and antitumor activity [81]. The trans-palladium(II) quinolylmethyl phosphonate complexes which exhibit potential *in vitro* anti-tumour activity [82]. The Pd(II) complexes of S-alkylthiosemicarbazone and thiosemi carbazone exhibited promising activity against bacteria such as *Candida albicans*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Proteus mirabilis*, *Escherichia coli* [83]. The NSO tridentate and NS bidentate thiosemicarbazone complexes with Pd(II) exhibited significant anticancer antibacterial, antifungal and antibacterial activity [76, 84, 85].

1.5.3 Platinum complexes with thiosemicarbazone Schiff base compounds

Cisplatin was synthesized by Pyrone in 1844 and was permitted for the treatment against human cancer in 1978. However, the biological effect of this compound on cancer was accidentally discovered by Rosenberg and co-workers in 1965. The emergence of modern medicinal chemistry, which was inspired by the discovery of cisplatin, has been contributed by the extensive knowledge and efforts of medicinal chemists on the coordination and biological properties of metal ions. The thiosemicarbazone moiety containing Schiff base ligands chelate with Pt(II) shows higher activity against antitumor and anticancer than their ligands; while metal-based drugs are more promising and convenient as therapeutic agent [86-89]. The complexes of Pt(II) with 4(N)- substituted derivatives of 2-acetylpyridine thiosemicarbazone

exhibited potential antitumor, anticancer, antibacterial, antineoplastic and cytogenetic activities [88, 90, 91]. The NS coordinating site containing carbazate chelated to Pt(II) exhibits potential antibacterial and anticancer activity [92].


1.6 Antiproliferative activities of transition metal complexes of Schiff base compounds

Cancer is a deadly disease occurring both in male and female across the world. Almost half of all male and one-third of all female are diagnosed with cancer [93]. It is identified that one-quarter of adults' mortality is because of cancer [94]. However, cancer treatment is a massive task for oncologists to get feasible remedy with reasonable cost. Nowadays, many drugs are generally available to treat breast cancer, cervical and colon cancer such as Tamoxifen, 5-fluorouracil (5-FU) and Bevacizumab. However, these chemotherapeutic drugs are often less effective and sometimes cancer cells may exhibit or develop resistance to these drugs [95]. It was observed that DNA is one of the primary intracellular targets for anti-cancer drugs. It is thus important to understand the different binding modes of these small molecules towards DNA. The recognised noncovalent binding modes of small molecules to DNA are intercalative binding, groove binding and external electrostatic binding [96, 97]. Thiosemicarbazones Schiff base complexes with Cu(II) and hydrazine with Mn(II) exhibit potential antitumor and anticancer activity [98-101]. The tetradentate N^2O^2 Schiff bases complexes with Pt(II) and Pt(IV) exhibit promising anticancer activity [102] while the Cu(II) complexes of bidentate N^2 Schiff base exhibit affordable anticancer and antitumor activity [103].

1.7 Anti-bacterial activities of Nickel, Palladium and Platinum complexes with thiosemicarbazone Schiff base

Most of the Schiff bases have been shown to have a wide range of biological activities attributed to the -HC=N- imine functional group [104-107]. Biological activities have been shown to take place through hydrogen bonding (Fig. 1.8) of the imine of Schiff bases to the active site of the cell [108].

Metal coordinated Schiff base compounds are more effective in biological activity than uncoordinated ligands [109-111]. Thiosemicarbazones Schiff bases show uncommon coordination due to two factors. The factors responsible for uncommon coordination are: (a) intramolecular hydrogen bonding which reduces the ability of bonding of the lone pair electrons of the imine nitrogen; and (b) the bulky group on the chelating ligand (Scheme 1.10) [112].



Scheme 1.10. The possible bonding to metal and hydrogen bonding.


Transition metal complexes containing nitrogen, oxygen and sulphur donor sites possess unique configuration, structural lability and show biocidal activities [113]. The environment around the metal centre such as its coordination geometry, coordinated site and donor group are the key point for biological activities [114]. Thiosemicarbazone derivatives coordinated to metal ion forming chelates arise biological activities. The lipophilicity of the compounds regulates the access of constituents into the cell [115-117]. The peptidoglycan cell membrane of gram-positive bacteria is thicker than gram-negative bacteria, therefore Minimum Inhibition

Concentration (MIC) can be more for gram-positive bacteria than gram-negative bacteria due to different rate of the inoculation of compound diffusion [118].

The Pd(II) complexes with Schiff base derived from dithiocarbazic acids show potential biological activities due to their kinetic lability and thermodynamic stability [68, 119]. Nowadays, dangerous life-threatening contagious diseases initiated by multi-drug resistant Gram-positive and Gram-negative bacteria have been detected in alarming levels throughout the world [120]. Thiosemicarbazones, and nitrogen and sulphur containing chelating agents are becoming highly important in coordination chemistry and biology due to their physico-chemical properties and pharmacological properties [92, 121, 122].

1.8 Heterocyclic and thiosemicarbazone Schiff base compounds and their complexes

Thiosemicarbazones, particularly $(R^1R^2C^2=N^3-N^2(H)-C^1(=S)N^1R^3R^4)$ are very important compounds with S and N coordinating centres; their coordination chemistry was firstly noted in the early sixties [123]. Ali and Livingstone [30] initially studied the chemistry of thiosemicarbazone which was successfully reviewed in 1975 by Campbell [28]. Patil and Shah in 1980 and subsequently Dave and Thampy in 1981 had reported the square planar Ni(II) complexes (Scheme 1.11) with 2-hydroxyacetophenone and its substituted derivatives thiosemicarbazone [124, 125].




Scheme 1.11. The square planar Ni(II) complexes of thiosemicarbazone Schiff base ligands.

Metal-thiosemicarbazone coordination chemistry was studied in 1985 by Padhye and Kauffman [45], later by West et al in 1991 and 1993 [121, 126]. The Pd(II) and Pt(II) tetranuclear complexes with *p*-isopropylbenzaldehyde thiosemicarbazone was reported by Quiroga and Pérez in 1998 [79]. Further studies in this area was carried out by Casas et al in 1999 and 2000 [127, 128]. The reaction mixture of thiosemicarbazide and aldehyde or ketone was refluxed in methanol and in the presence of molecular sieves to synthesize thiosemicarbazone Schiff base compounds [43].


The synthesis of first row transition metal complexes with thiosemicarbazone were basically prepared from metal acetates, sulphates, perchlorates, halides or nitrates in organic solvent at room temperature or at refluxing temperatures [54, 129-137]. The complexes with 4*d* and 5*d* transition metals with thiosemicarbazone were prepared by different routes depending on the type of metals. The Pd(II) and Pt(II) complexes were synthesized using M_2PdCl_4 and M_2PtCl_4 (M = Li, K) [54, 87, 138-142].

Ni(II) form different types of complexes which are mononuclear and polynuclear with Schiff base chelating ligand was reported by Leovac et al in 2007 and Suni et al in 2007 [32, 143]. The Ni(II) is usually observed to coordinate with anionic bidentate or tridentate ligand via S or O donor site. The Ni(II) forms square planar complexes where the fourth position was occupied with NCS (N-bonding), Br, Cl, MeCO₂, PPh₃, and NH₃, while the thiosemicarbazone ligand was tridentate in the complexes **15-20** (Scheme 1.12) [144-150].




Scheme 1.12. The synthesized complexes of thiosemicarbazone Schiff base ligand to nickel.

The N³ and S coordinating site containing thiosemicarbazone form trans square planer [PdL₂] complexes, **21-24** of Pd(II) (Scheme 1.13) [151-154]. At the same time Vila and Pereira reported the square planar [PdL₂]-CHCl₃ **25** (Scheme 1.13) complex with cis-position of S-donor site [155].



Scheme 1.13. The synthesized complexes of thiosemicarbazone Schiff base ligand to palladium.

Thiosemicarbazone uninegative tridentate NNS coordinating sites ligand form Pt(II) complexes with general formulae of [PtLY], shown as **26-30** (Scheme 1.14), whereas X = N or P [88, 90, 139, 142, 156]. The dinegative tridentate ONS coordinating site and the same ligand as neutral monodentate via S coordinating site form square planar Pt(II) complex, [PtL(H₂L)] **31**, whereas X = O [157].



Scheme 1.14. The synthesized complexes of thiosemicarbazones Schiff base ligand to platinum.

1.9 Anticancer and antibacterial activities of thiosemicarbazone and hydrazone Schiff base compounds and their complexes

The interest of Schiff base and its complexes with transition metals is increasing due to potential biological application [158]. Brockman and Thomson in 1956 had investigated the anti-leukemic activity of pyridine-2-carbaldehyde thiosemicarbazone but the compound was found to be toxic [159]. Antholine and Knight in 1976 reported the potential antitumor activity of iron and copper complexes of 5-substituted-2-formylpyridine thiosemicarbazones against tumor cell lines [160]. Dobek and Klayman in 1986 reported the remarkable antibacterial activity of 2-acetylpyridine-1-oxide thiosemicarbazones against *N. gonorrhoea*, *S. faecalis*, *N.*

meningitis and *S. aureus* [161]. Liu and Lin in 1992 observed the antitumor activity of 3- and 5-aminopyridine-2-carboxaldehyde thiosemicarbazones on L1210 leukaemia, whereas the 3-amino substituted complex was found to be more active [162]. Oxovanadium(IV) complexes of thiosemicarbazone of 2-formylpyridine showed potential *in vitro* activity against *E. coli* was reported by Maiti and Guha in 1988 [163]. The titanium and zirconium complexes of thiosemicarbazone derived from 2-acytylnaphtalene, 2-acytylthiopene, 2-acytylpyridine, and 2-acytylfuran exhibited potential activity against *E. coli*, *S. aureus*, *S. viridans* and *P. mirabilis* [164]. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone has been shown to have potential activity against mouse M109 lung carcinoma and A2780 human ovarian carcinoma [165]. Bindu et al. in 1998 investigated antibacterial activity against pathogenic bacteria of human *Salmonella typhi*, *S. aureus* and, *Shigella dysenteriae* using Cu(II) complexes of N-phenylsalicylaldehyde thiosemicarbazone, where they found that the complexes exhibited higher activity than the ligand [166]. Küçükgülzel et al in 1999 [167] studied the antibacterial activity against *Staphylococcus aureus* using ethyl-2-arylhydrazone-3-oxobutyrate derivatives. Kovala and Yadav in 2000 synthesized Pt(II) square planar complexes with 2-acetylpyridine thiosemicarbazone-N-Me [PtLCl] and tested against sophisticated ovarian cancer cell lines A2780/Cp8 and A2780. The IC₅₀ values of 0.14 and 0.08 µM obtained respectively was higher than cisplatin [88]. Kovala and Demertzi in 2001 and 2003 studied the square planar and distorted square planar complexes of Pt(II) with thiosemicarbazone that exhibit lethal effect against Gram (+) bacteria [87, 90]. Singh and Narang [168] carried out the study on antibacterial activity against *Escherichia coli* as well *Aspergillus niger* using Co(II), Ni(II), Zn(II), Cu(II) and Cd(II) complexes with acetophenone-4-aminobenzoylhydrazone and 4-hydroxyacetophenone-4-aminobenzoylhydrazone.

Savini and Chiasserini in 2004 [169] had reported the anticancer activity of 3- and 5-methylthiophene-2-carboxaldehyde α -(*N*)-heterocyclic hydrazone derivatives. 6-Methyl-2-formyl pyridine Schiff bases of S-methyldithiocarbazates ligand (Hmpasme) form complexes [Pd(mpasme)Cl], [Pt(mpasme)Cl] and [Pt(Hmpasme)Cl] with (Pd(II) and Pt(II) respectively and were investigated against human ovarian cancer (Caov-3) cell lines. The ligand and platinum complex showed remarkable activity but Pd(II) complex showed only weak activity was reported by Ali et al in 2006 [170]. Al-Sha'alan in 2007 [171] evaluated the antibacterial activity against *Staphylococcus aureus* and *Escherichia coli* using Cu(II), Ni(II), Co(II), Mn(II) and Fe(II) complexes with 7-chloro-4-(benzylidenehydrazo) quinolone. Pyridyl thiosemicarbazone and its transition metal complexes were tested for anti-bacterial activities. The higher inhibitory effect was found for complexes because of more lipophilicity of complexes than ligand [43]. The Pd(II) and Pt(II) complexes of 2-acetyl-4-methylthiazolethiosemi carbazone and 2-acetylpyrazinethiosemicarbazone exhibited potential activity against two human tumor cell lines HT-29 and HuTu-80 were reported in 2016 by Nimir et al [172]. Pt(II) complexes of methylhydrazine carbodithioate derivatives of indolin-2-one exhibited strong activity against HCT 116, MCF-7 was reported by Li et al in 2017 [173].

1.10 The Problem statement

The thiosemicarbazone and heterocyclic Schiff base compounds are important segment for chemistry, biology and medicinal chemistry. These compounds were synthesized by different techniques which gave low yield [174-176]. These compounds contain nitrogen, sulphur and oxygen together in the same molecule. The ONS and ONN group could be chelated strongly with transition metal ions. Very few

of these compounds have been reported complexed to group 10 transition metal ions in the literature. The percentage yield was not satisfactory and the synthetic procedures were not described explicitly.

These compounds and their transition metal complexes might have good biological and medicinal properties. *Cis-platin* was the first group 10 metal chelated complex to be used as an anti-cancer agent. It has been identified that the nitrogen moiety in *cis-platin* plays an important role in its anti-cancer activity. Similar complexes as *cis-platin* could be a potential chemotherapeutic agent for cancer treatment besides surgery and radiation therapy. Therefore, the comparative investigation against cancer cell lines using thiosemicarbazone and heterocyclic Schiff base ligands and their complexes with Group 10 metal ions, seems to be an interesting option to be investigated.

Dangerous life-threatening contagious diseases initiated by multi-drug resistant gram-positive and gram-negative bacteria have been increasing at an alarming rate across the world. Thiosemicarbazones, particularly nitrogen and sulphur containing chelating agents have shown promising activities against such bacteria. In addition, the phenolic OH containing groups have shown potential antibacterial and antifungal activities [177, 178]. From the literature review the Schiff base ligands and their complexes with Group 10 metal ions have not been investigated comparatively against gram-positive and gram-negative bacteria. These compounds could be the potential agent against diseases originating from microorganism.

1.11 Objective of the research work

In this work, some new Schiff base compounds will be synthesized and complexed with group 10 transition metal ions. These complexes and their ligands will be subjected to the characterization and cytotoxicity and bacteriological studies. The specific objectives to fulfil the aim of this study are as follows:

1. To synthesize and fully characterize thiosemicarbazone, heterocyclic and oxygen bis Schiff base compounds having ONS and ONN coordination sites.
2. To synthesize and fully characterize the Ni(II), Pd(II) and Pt(II) complexes with the above Schiff base ligands.
3. To evaluate of their anti-proliferative activities against breast cancer (MCF-7), colon cancer (HCT 116), cervical cancer (Hela) and normal (endothelial cell Ea.hy926) cell lines.
4. To test of their antibacterial activities against gram-positive *Staphylococcus aureus* and gram-negative *Escherichia coli*.

CHAPTER TWO

EXPERIMENTAL

2.1 Material and measurement


All the reagents and chemicals were purchased from Sigma-Aldrich and Fluka. The solvents were purified with prescribed standard procedure [179]. FTIR data were obtained using the Perkin Elmer System 2000 FTIR as KBr disc in the range 400-4000 cm^{-1} . The melting points were recorded using a Gallenkamp melting point apparatus (model 7936B, England). The ^1H and ^{13}C NMR were recorded with Bruker Avance III 500 MHz and 125 MHz spectrophotometer respectively using TMS as internal standard and DMSO- d_6 , $\text{CD}_3\text{OD}-d_4$, $\text{OC}(\text{CD}_3)_2-d_6$, and CDCl_3 as solvent. X-ray crystallographic data were recorded on a Bruker SMART APEXII CCD area-detector diffractometer using graphite-monochromated $\text{MoK}\alpha$ radiation ($\lambda = 0.71073\text{\AA}$) in the range 100 K to 294 K. The data were collected and reduced using APEX2 and SAINT. The structures were solved using the SHELXS-97 program package, and refined using the SHELXL-97 program package. All none hydrogen atoms were anisotropically refined. Molecular graphics were created using SHELXTL-97.

2.2 Experimental procedure for the ligands synthesis

2.2.1 General procedure for the synthesis of Schiff base ligands

The aldehyde was dissolved in requisite amount of methanol or ethanol (20.0 mL) and 0.20 mL glacial acetic acid was added as catalyst [49, 90-91, 179]. The corresponding amine was dissolved in methanol or ethanol then added to the aldehyde solution. The resulting solution was refluxed for 4 h, in a round bottomed flask equipped with magnetic stirrer and water condenser. The product was dried under


reduced pressure then washed with the appropriate solvent. The product was recrystallized with slow evaporation of solvent at room temperature and diffusion technique.



Scheme 2.1. Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and carbothioamide derivatives.

Table 2.1. Ligand labels and their identity for compounds in Scheme 2.1.


Sample Code	R ₁	R ₂	R ₃	R ₄	R ₇
L1	OH	CH ₃	H	H	CH ₃
L2	OH	CH ₃	H	H	C ₆ H ₁₁
L3	OH	NO ₂	H	OCH ₃	C ₆ H ₁₁
L4	OH	NO ₂	H	OCH ₃	CH ₃
L5	OH	t-butyl	H	H	C ₆ H ₁₁
L6	OH	H	H	t-butyl	C ₆ H ₁₁
L7	H	OH	OCH ₃	H	C ₆ H ₁₁
L8	OH	H	OH	H	CH ₃
L9	OH	H	H	H	C ₆ H ₁₁
L10	H	OH	OCH ₃	H	CH ₃



Scheme 2.2. Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and pyridine derivatives.

Table 2.2. Ligand labels and their identity for compounds in Scheme 2.2.


Sample Code	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
L11	OH	H	H	CH ₃	H	CH ₃
L12	OH	H	H	CH ₃	CH ₃	H
L13	OH	CH ₃	H	H	CH ₃	H
L14	OH	CH ₃	H	H	H	CH ₃
L15	OH	H	H	OCH ₃	H	CH ₃
L16	H	OH	OCH ₃	H	CH ₃	H



Scheme 2.3. Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and imidazole derivatives.

Table 2.3. Ligand labels and their identity for compounds in Scheme 2.3.

Sample Code	R ₁	R ₂	R ₃	R ₄	E
L17	H	OH	OCH ₃	H	N
L18	H	OH	OCH ₃	H	S



Scheme 2.4. Synthesis of Schiff base ligands. The scheme shows the reaction between benzaldehyde derivatives and 4,4'-oxydianiline.

Table 2.4. Ligand labels and their identity for compounds in Scheme 2.4.

Sample Code	R ₁	R ₂	R ₃	R ₄
L19	OH	NO ₂	H	OCH ₃
L20	OH	CH ₃	H	H
L21	H	OH	OCH ₃	H

2.2.2 Synthesis of 2-(2-hydroxy-3-methylbenzylidene)-*N*-methylhydrazine-1-carbothioamide (L1)

The 0.68 g (5.00 mmol) 2-hydroxy-3-methylbenzaldehyde was dissolved in 20.0 mL methanol, 0.20 mL glacial acetic acid was added and the mixture was refluxed for 30 minutes. A solution of 0.52 g (5.00 mmol) *N*-methyl hydrazinecarbothioamide in 20.0 mL methanol was added dropwise with stirring to the aldehyde solution. The resulting colourless solution was heated under reflux for 4 h with stirring. The crude product was washed with 5.0 mL *n*-hexane. The recovered product was dissolved in DMSO for purifying and recrystallization. Light yellow coloured single crystals suitable for X-ray diffraction study was obtained by slow evaporation of the solvent. Colour: Light yellow; M. P.: 181-182 °C; Yield (%): 94. anal. Cal. For C₁₀H₁₃N₃OS (FW: 223.29 g mol⁻¹); C, 53.74; H, 5.83; N, 18.81; Found: C, 53.71; H, 5.79; N, 18.83

%. ^1H NMR (500 MHz, DMSO- d_6 , Me $_4$ Si ppm): δ 11.38 (s, N-NH), δ 9.39 (s, OH), δ 8.34 (s, HC=N), δ 8.44 (q, CS-NH), δ 7.42-6.81 (multiplet, aromatic), δ 3.00 (d, J = 4.5 Hz, N-CH $_3$), δ 2.20 (s, Ph-CH $_3$). The ^{13}C NMR (DMSO- d_6 , Me $_4$ Si ppm): δ 177.48 (C=S), δ 154.24 (C=N), δ 143.64-119.10 (C-aromatic), δ 31.05 (N-CH $_3$), δ 15.91 (Ph-CH $_3$) ppm. IR (KBr pellets $\nu_{\text{max}}/\text{cm}^{-1}$): 3418 ν (NH), 3133 ν (OH), 2983(NC-H_3 , sp^3), 1618 ν (C=N), 1553 ν (C=C, aromatic), 1270 ν (C=S), 1251 ν (CH, bend., aromatic), 1085 ν (C-O). 1043 ν (C-N).

2.2.3 Synthesis of *N*-cyclohexyl-2-(2-hydroxy-3-methylbenzylidene)hydrazine -1 -carbothioamide (L2)

The 0.68 g (5.00 mmol) 2-hydroxy-3-methylbenzaldehyde was dissolved in 20.0 mL methanol. 0.20 mL glacial acetic acid was added to the mixture and was refluxed for 30 minutes. A solution of 0.87 g (5.00 mmol) *N*-cyclohexylhydrazine carbothioamide in 20.0 mL methanol was added drop wise with stirring to the aldehyde solution. The resulting colourless solution was refluxed for 4 h with stirring. The colourless precipitate was obtained with evaporation of solvent. The crude product was washed with 5.0 ml *n*-hexane. The recovered product was dissolved in acetonitrile and purified by recrystallization. A colourless single crystals suitable for X-ray diffraction was recovered with slow evaporation of acetonitrile. M. P.: 240-241 °C; Yield (%): 93. anal. Cal. For C $_{15}$ H $_{21}$ N $_3$ OS (FW: 291.41 g mol $^{-1}$); C, 61.77; H, 7.21; N, 14.42; Found: C, 61.81; H, 7.19; N, 14.42 %. ^1H NMR (500 MHz, DMSO- d_6 , Me $_4$ Si ppm): δ 11.27 (s, N-NH), δ 9.51 (s, OH), δ 8.34 (s, HC=N), δ 8.05 (d, J = 8.35 Hz, CS=NH), δ 7.39-6.81 (multiplet, aromatic-H), δ 2.20 (s, Ph-CH $_3$), δ 1.87-1.14 (multiplet, cyclohexyl-H) ppm. The ^{13}C NMR (DMSO- d_6 , Me $_4$ Si ppm): δ 175.79 (C=S), δ 154.29 (C=N), δ 143.76-119.17 (C-aromatic), δ 15.93(CH $_3$), δ 52.87-

24.90(C-cyclohexyl) ppm. IR (KBr pellets $\nu_{\max}/\text{cm}^{-1}$): 3364 $\nu(\text{NH})$, 3148 $\nu(\text{OH})$, 2989(CH_3), 2931 and 2854 $\nu(\text{CH, cyclohexyl})$, 1620 $\nu(\text{C=N})$, 1540 $\nu(\text{C=C, aromatic})$, 1268 $\nu(\text{C=S})$, 1218 $\nu(\text{CH, bend., aromatic})$, 1122 $\nu(\text{C-O})$. 1075 $\nu(\text{C-N})$.

2.2.4 (*E*)-*N*-cyclohexyl-2-(2-hydroxy-5-methoxy-3-nitrobenzylidene)hydrazine-1-carbothioamide (L3)

The 2-hydroxy-5-methoxy-3-nitrobenzaldehyde 0.76 g (5.00 mmol) was dissolved in 20.0 mL methanol, 0.20 mL glacial acetic acid was added and the mixture was refluxed for 30 minutes. *N*-cyclohexylhydrazinecarbothioamide 0.54 g (5.00 mmol) solution in 20.0 mL methanol was added dropwise with stirring to the aldehyde solution. The resulting deep orange solution was refluxed for 4 h with stirring. A reddish orange precipitate was formed. The precipitate was filtered and washed with 5.0 mL hot methanol and 5.0 mL *n*-hexane. The recovered product was dissolved in a mixture of THF and toluene (4:1) to attempt purification by recrystallization. Only a reddish orange solid product was isolated. The product was washed with 5.0 mL methanol and 5.0 mL of *n*-hexane. Colour: Reddish Orange; M. P.: 245-246 °C; Yield (%): 98. Anal. Cal. For $\text{C}_{15}\text{H}_{20}\text{N}_4\text{O}_4\text{S}$ (FW: 352.41 g mol^{-1}); C, 51.10; H, 5.60; N, 15.80; Found: C, 51.15; H, 5.58; N, 15.70 %. $^1\text{H NMR}$ (500 MHz, DMSO-d_6 , Me_4Si ppm): δ 11.57 (s, N-NH), δ 10.40 (s, OH), δ 8.41 (s, HC=N), δ 8.21 (d, $J = 8.55$ Hz, CS-NH), δ 8.03 (s, aromatic-H), δ 7.54 (s, aromatic-H), δ 3.83 (s, Ph-OCH₃), δ 1.86-1.14 (multiplet, cyclohexyl-H). The $^{13}\text{C NMR}$ (DMSO-d_6 , Me_4Si ppm): δ 175.87 (C=S), δ 151.51 (C=N), δ 145.55-108.91 (C-aromatic), δ 56.02 (Ph-OCH₃), δ 52.94 - 24.97 (C-cyclohexyl). IR (KBr pellets $\nu_{\max}/\text{cm}^{-1}$): 3363 $\nu(\text{NH})$, 3123 $\nu(\text{OH})$, 2934 $\nu(\text{CH}_2, \text{cyclohexyl})$, 1584 $\nu(\text{C=N})$, 1532 $\nu(\text{C=C, aromatic})$, 1431 $\nu(\text{C-H, } sp^3, \text{ bend})$, 1249 $\nu(\text{NO}_2)$, 1213 $\nu(\text{C=S})$, 1052 $\nu(\text{C-N})$, 937 $\nu(\text{N-N})$.